<- Go Home
Zosano Pharma Corporation
On December 7, 2022, Zosano Pharma Corporation went out of business as per its Chapter 11 liquidation filing under bankruptcy. Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.
Market Cap
$980.00
Volume
138.0K
Cash and Equivalents
$13.5M
EBITDA
-$29.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$20.2M
Profit Margin
3063.13%
52 Week High
$24.80
52 Week Low
$0.00
Dividend
N/A
Price / Book Value
0.00
Price / Earnings
-0.00
Price / Tangible Book Value
0.00
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$30.9M
Return on Equity
192.97%
Return on Assets
-41.86
Cash and Short Term Investments
$13.5M
Debt
$6.0M
Equity
$14.1M
Revenue
$659.0K
Unlevered FCF
-$17.9M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium